Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-752 in Dengue Infection
NCT05466240Phase 2Terminated
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
A Phase 2 trial of arbemnifosbuvir in dengue fever, sponsored by Atea Pharmaceuticals. Started Apr 2022; status: terminated.
02
Drugs
arbemnifosbuvir
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05466240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466240.